References
- Del TaccaMDPasqualettiGGoriGComparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteersTher Clin Risk Manag2013930331123901278
- Committee for Medical Products for Human use, European Medicines AgencyGuideline on the investigation of bioequivalence82010 [webpage on the Internet]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdfAccessed September 14, 2013
- Health Products and Food Branch. Health CanadaGuidance document: Conduct and Analysis of Comparative Bioavailability52010 [webpage on the Internet]. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/bio/gd_cbs_ebc_ld-eng.pdfAccessed September 14, 2013
- DaviesNMSkjodtNMClinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drugClin Pharmacokinet19993611512610092958
- TangsucharitPKampanJKanjanawartSBioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteersInt J Clin Pharmacol Ther20094763864219825327
- WelageLSKirkingDMAscioneFJGaitherCAUnderstanding the scientific issues embedded in the generic drug approval processJ Am Pharm Assoc (Wash)20014185686711765111
- State Food and Drug Administration of ChinaGuideline for Bioavailability and Bioequivalence studies of pharmaceutical formulations [in Chinese] Available from: http://www.sfda.gov.cn/WS01/CL0055/10368.htmlAccessed September 13, 2013
- ASEAN Guidelines for the Conduct of Bioavailability and Bioequivalence Studieshttp://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/western_medicines/files_guidelines.Par.59188.File.dat/ACTR_GuidelinesforConductofBioavailabilityandBioequivalenceStudies_Nov05.pdfAccessed September 13, 2013
- SalemMSAlkaysiHNGharaibehAMGharaibehNMBadwanAABioequivalence of two oral dosage forms prepared from different polymorphic modifications of tenoxicamJ Clin Pharm Ther1994192032077962225
- JiangTRongZXuYPharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizersClin Drug Investig20133319
- Yong ChungJJung LeeYBok JangSAhyoung LimLSoo ParkMHwan KimKCYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence studyTher Drug Monit201032677220010459
- González-VacarezzaNAbad-SantosFCarcas-SansuanAUse of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6Pharmacogenomics JJune 26, 2012
- PattersonSDZariffaNMDMontagueTHHowlandKNontraditional study designs to demonstrate average bioequivalence for highly variable drug productsEur J Clin Pharmacol20015766367011791897
- RodriguesADImpact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?Drug Metab Dispos2005331567157516118328
- RealGenehttp://www.realgene.it/dettaglio_prodotto.asp?language=eng&id_a=42Accessed September 13, 2013
- ZhouQChenQXRuanZRYuanHXuHMZengSCYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokineticsPharmazie20136818719423556337
- DaiDPXuRAHuLMCYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency databasePharmacogenomics J Epub2122013
References
- Del TaccaMPasqualettiGGoriGComparative pharmacokinetic and pharmacodynamics evaluation of branded formulations of meloxicam in healthy male volunteersTher Clin Risk Manag2013930331123901278
- European Medicines AgencyGuideline on the investigation of bioequivalence2010 Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdfAccessed October 15, 2013
- AhmadMBioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjectsActa Pol Pharm20116811511921485709
- HasanSMBioequivalence studies of two brands of meloxicam tablets in healthy Pakistani volunteersPak J Pharm Sci20092219920419339233
- TangsucharitPBioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteersInt J Clin Pharmacol Ther20094763864219825327
- GschwendMHPharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjectsArzneimittelforschung20075726426817598697
- ChassaingCSchmidtJEschalierACardotJMDubrayCHyperalgesia induced by cutaneous freeze injury for testing analgesics in healthy volunteersBr J Clin Pharmacol200661438939716542199
- MeredithPBioequivalence and other unresolved issues in generic drug substitutionClin Ther2003252875289014693311
- SchmidJBuschUHeinzelGBozlerGKaschkeSKummerMPharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjectsDrug Metab Dispos199523120612138591720
- ChesneCGuyomardCGuillouzoASchmidJLudwigESauterTMetabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4Xenobiotica1998281139493314
- XieHGPrasadHCKimRBSteinCMCYP2C9 allelic variants: ethnic distribution and functional significanceAdv Drug Deliv Rev2002541257127012406644
- RodriguesADImpact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?Drug Metab Dispos2005331567157516118328
- Vianna-JorgeRPeriniJARondinelliESuarez-KurtzGCYP2C9 genotypes and the pharmacokinetics of tenoxicam in BraziliansClin Pharmacol Ther200476182615229460
- SiDGuoYZhangYYangLZhouHZhongDIdentification of a novel variant CYP2C9 allele in ChinesePharmacogenetics20041446546915226678
- European Medicines AgencyNote for guidance on the investigation of bioavailability and bioequivalence Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003519.pdfAccessed October 15, 2013